Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the ...

Pfizer’s vaccine – called Abrysvo – is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, the same label that the FDA gave to ...

Pfizer's enhanced vaccine portfolio represents another pillar of Pfizer's response. Abrysvo and the next-gen pneumococcal vaccine are two strong blockbuster candidates for the long run.

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

News about Pfizer Inc., including commentary and archival articles published in The New York Times.